The global seasonal allergy market enjoys a valuation of US$ 1.15 Billion in 2022, and it is further projected to expand at a CAGR of 7.8% over the forecasted years. According to a recent study by Future Market Insights, tablets/capsules by form leading the market with a share of about 37.1% in the year 2022, within the global market.
Market Outlook
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 1.15 Billion |
| Market Value 2033 | US$ 2.58 Billion |
| CAGR 2023 to 2033 | 7.8% |
| Market Share of Top 5 Countries | 62.1% |
| Key Market Players | Merck KGaA, Johnson & Johnson, Allergopharma, Sanofi SA, McNeil Consumer Healthcare, Genentech Inc., GlaxoSmithKline PLC, Leti Pharma, Alerpharma S.A, Allergan, Inc., Meda Pharmaceuticals, Inc, Novartis International AG, Bausch Health Companies Inc., Allergopharma, ALK Abello, Stallergenes, Greer, Allergy Therapeutics, Aimmune Therapeutics, Biomay AG, HAL Allergy Group, Bayer, AstraZeneca |
Seasonal allergies, like other allergies, develop when the body's immune system overreacts to a trigger in the environment, usually in the spring, summer, or fall when specific plants pollinate. A growing number of producers have identified allergies as a viable market, and with the help of a research and development team, they are delivering fresh, cutting-edge therapy and treatment options to the market, expanding the range of already available treatments. A large portion of people are still affected by seasonal allergies yearly.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 7.8% between 2023 and 2033, owing to the rising prevalence of allergic diseases.
The global market holds around 5.7%share of the overall global allergy treatment market with a value of around US$ 20.2 Million, in 2022.
Longer pollen seasons during warmer temperatures or higher carbon dioxide emissions brings about higher quantities of pollen. These are the key contributors to the seasonal allergies affecting an individual. The incidence rate and prevalence rate of seasonal allergies are growing rapidly owing to which the demand for available treatments is expected to increase over the forecast period.
Antihistamines, decongestants, nasal corticosteroids, allergen immunotherapy, and leukotriene receptor antagonists are some of the most well-liked treatments for seasonal allergies. Antihistamines dominate the market since they are one of the most widely used and widely prescribed medications for the treatment of allergies, both with and without a prescription.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 2.58 Billion during the year 2033.
This creates an enormous opportunity for the manufacturer to explore the seasonal allergy market. Several biopharma businesses with tested technology and cutting-edge treatment choices that are unique and have been approved have emerged as a result of the life science industry's entry into the pharmaceutical sector. This enables medical professionals to rely on these novel treatment possibilities.
For instance, allergy immunotherapy as a treatment has proven to be successful in multiple clinical trials. Such as high-dose, standardized vaccinations are used in subcutaneous injection immunotherapy (SCIT). These medications typically contain 5–20 mcg of the main allergen. SCITs are given as maintenance injections every month. Also, sublingual allergy immunotherapy (SLIT) involves the sublingual space's unique, tolerance-promoting immune cells, also known as oral Langerhans cells. Liquid antigens (drops) and pills are the two therapeutic options for SLIT.
Overall, it is anticipated that the market for seasonal allergies will rise over the coming years as more research and development are put into creating fresh, efficient treatment choices.
Principal Consultant
The market is experiencing a decline due to the adverse effects associated with allergy shots and tablets.
Periodic injections are administered over time as allergy shots. Immunotherapy for allergies is a protracted treatment that might last anywhere between three and five years. It entirely depends on the kind and degree of allergy.
Each allergy shot contains a very small amount of the exact ingredients or substances that cause allergic responses.
Patients frequently discontinue therapy in the middle of the procedure due to extended treatment schedules, age, health, physical location, and financial constraints.
The time associated with the treatment may hinder market growth.
The USA dominates the North American region with a global market share of around 30.8% in 2022. In the United States, the importance of artificial intelligence (AI) in medical sciences cannot be overstated. The healthcare industry in the US is one of the largest in the world, and it faces numerous challenges, such as rising costs, an aging population, and a shortage of healthcare professionals.
AI has the potential to address many of these challenges by improving the accuracy and efficiency of medical diagnosis and treatment. For instance, in the case of seasonal allergies, AI The Weather Channel data science team has been trying to develop a tool to assist seasonal allergy sufferers as spring progresses and summer draws closer. Allergy Insights with Watson, a new service that uses AI to assist forecast seasonal allergy risk in the United States, is freely accessible on The Weather Channel app and weather.com.
In order to aware people in making the more appropriate decisions and preparing for allergy season, united states in going to witness an exponential growth in the global market
China has a market share of 9.5%, with a market value of US$ 109.9 Million in the global seasonal allergy market in 2022.
In China, allergy immunotherapy (AIT) has been practiced for more than 60 years. The Chinese College of Allergy and Asthma (CCAA), a specialized branch of CDMA that serves as the primary certifying body for AIT, was formed in 2016 with the backing of the Chinese Medical Association (CMA) and the Chinese Medical Doctors Association (CMDA). Chinese allergists and researchers have made significant advancements in the creation of AIT. Chinese allergists and researchers have published a large number of articles globally that include original research investigations, systematic reviews, case studies, and clinical trials. Sublingual immunotherapy (SLIT) is starting to gain popularity in China, where traditional subcutaneous immunotherapy (SCIT) is now the favored AIT.
Similar to the United States, immunotherapy is popular in China and it is expected to establish a steady growth in the coming years.
Germany holds a market share of 8.7% in 2022 in the global seasonal allergy market, owing to the presence of many established players in European countries.
Germany is a global leader in biotechnology, and the environment for the growth of commercial biotechnology is only improving. This has a favorable impact on the growth of new businesses that specialize in this industry. There were more businesses between 2015 and 2019 by 20.7%. Germany continues to be the top European nation for funding the biotechnology sector. 78% of the industry's overall budget in 2019 was generated through venture capital and initial public offerings (IPOs). About 70% of all businesses in Germany use biotechnology for medical purposes, which is particularly significant in light of the recent developments brought on by COVID-19.
Germany is strengthening its manufacturing and development of novel drugs which will positively grow the market in the future.
India holds a share of around 6.6% in the global market in 2022.
The prevalence of allergies and asthma is increasing in India, and it has turned into a serious health issue. Symptoms can range from mild rhinitis to severe asthma, and even life-threatening anaphylaxis. This subcontinent has a very broad "allergen repertoire" because of its distinct climatic conditions, flora, and dietary customs. To make an accurate diagnosis and create immunotherapeutic vaccines, allergy-eliciting chemicals must be correctly identified, purified, and molecularly characterized. Although there are many reports on common allergies, the majority of these studies relied on early allergen detection and identification. Recombinant technologies and structural biology have only been used to characterize a small number of these allergen compounds.
There are still millions of cases of the disease worldwide, despite India's prevalence rates generally being lower than those of high-income countries. Due to the large number of patients, Indian biopharmaceutical companies must enhance their supply of treatment medications.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Tablets/Capsules are mostly favored by patients suffering from allergies. It has contributed US$ 427.4 Million to the global market in 2022.
Because of its durability and patient acceptability, the tablet is the most commonly utilized dosage form out of all those that are available. As a result, the coating plays a crucial role in the tablet's composition. The superior aesthetic qualities, such as color, texture, mouth feel, and flavor masking, depending on the film and sugar coatings. This makes tablets/capsules the most lucrative form.
OTC led the global market with over 76.0% value share in 2022. Customers find it simpler to buy OTC medications because they are widely accessible and may be purchased without a prescription. People can save time and money by not having to wait for prescriptions to be filled or make appointments with doctors. More people can afford OTC medications because they are often less expensive than prescription medicines.
Oral is mostly preferred by patients. It has a market share of 36.6% in the global market in 2022. Oral drugs are uncomplicated to administer, patients can take them at home without a doctor's supervision. Oral drugs are advantageous for those with chronic illnesses who require long-term care. Oral drugs are typically less expensive than those administered intravenously or orally, which necessitate more specialized equipment and physician oversight.
Antihistamines have a market share of 46.0% in the global market in 2022.
The ease of use and accessibility of over-the-counter antihistamines is high. Second-generation antihistamines are also thought to be a better option. However, each one must be assessed based on their particular efficacy and safety.
Hospital pharmacies hold a market share of 35.9% during the year 2022. Hospitals are the primary locations where readily available, licensed, and approved medication can be found. By collaborating with doctors, nurses, and pharmacy staff to provide the proper medications and supplies during treatment procedures, hospital pharmacies can significantly improve patient care. Hospitals can exceed their patient satisfaction goals with the guarantee of improved patient outcomes. Due to the extensive treatment offered in hospital settings, the category is predicted to expand at a profitable rate throughout the projection period.
Collaboration with scientific and research foundations to increase public awareness and receiving product approvals from regulatory bodies are the key strategies opted by key players within this market space.
Similarly, recent developments related to companies within the seasonal allergy market space have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, the United kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa and South Africa |
| Key Market Segments Covered | Form, Prescription Type, Route of Administration, Treatment, Distribution Channel |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The seasonal allergy market is anticipated to go up from US$ 1.22 billion in 2023 to US$ 2.58 billion by 2033, exhibiting a CAGR of 7.8%.
With a 5.7% CAGR between 2018 and 2022, the seasonal allergy market size reached US$ 1.15 billion in 2022.
Given its prevalent allergenic flora and demand for effective treatments, the United States stands as the dominant market for seasonal allergy products.
Seasonal allergy market trends include rising allergen sensitization, personalized treatment demand, and improved allergy management methods.
Prominent market players such as Merck KGaA, Johnson & Johnson, Allergopharma, Sanofi SA, McNeil Consumer Healthcare, and Genentech Inc. dominate the seasonal allergy market.
1. Executive Summary | Seasonal Allergy Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Disease Epidemiology 4.1.1. Prevalence Population 4.1.2. Diagnosed Prevalence Cases 4.1.3. Severity Specific Cases 4.2. Regulatory Guidelines 4.3. Patient Treatment Regime 4.4. PESTLE Analysis 4.5. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Life Expectancy Outlook 5.1.4. Pharmaceutical Spending 5.1.5. Global Allergy Treatment Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Increase Prevalence of Seasonal Allergy 5.2.2. Diagnostic Rate (%) 5.2.3. Treatment Seeking Rate (%) 5.2.4. Cases treated with Allergic Conditions 5.2.5. Overall Cost of Treatment 5.2.6. Recent Advancements In Technology 5.2.7. Regulatory Framework 5.2.8. Key Strategic Developments By Market Players 5.2.9. Adverse Effects May Impact the Market Growth 5.2.10. Growing Investment in Healthcare Sector 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity 6. COVID-19 Crisis – Impact Assessment 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Form 6.1.2. Revenue By Prescription Type 6.1.3. Revenue By Route of Administration 6.1.4. Revenue By Treatment 6.1.5. Revenue By Distribution Channel 6.1.6. Revenue By Country 6.2. 2022 Market Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Form 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis, By Form, 2018 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Form, 2023 to 2033 8.3.1. Tablets/Capsules 8.3.2. Liquid 8.3.3. Creams & Lotions 8.3.4. Drops 8.3.5. Spray 8.4. Market Attractiveness Analysis By Form 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Prescription Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis, By Prescription Type, 2018 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Prescription Type, 2023 to 2033 9.3.1. OTC 9.3.2. Prescription based 9.4. Market Attractiveness Analysis By Prescription Type 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis, By Route of Administration, 2018 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 10.3.1. Oral 10.3.2. Intranasal 10.3.3. Sublingual 10.3.4. Sub Cutaneous 10.3.5. Intravenous 10.4. Market Attractiveness Analysis By Route of Administration 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis, By Treatment, 2018 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 11.3.1. Antihistamines 11.3.2. Decongestants 11.3.3. Nasal Corticosteroids 11.3.4. Allergen Immunotherapy 11.3.5. LeUnited kingdomotriene Receptor Antagonists 11.4. Market Attractiveness Analysis By Treatment 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2018 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 12.3.1. Hospital Pharmacies 12.3.2. Supermarkets/Hypermarkets 12.3.3. Online Pharmacies 12.3.4. Retail Pharmacies 12.3.5. Specialty Clinics 12.3.6. Others 12.4. Market Attractiveness Analysis By Distribution Channel 13. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. East Asia 13.3.5. South Asia 13.3.6. Oceania 13.3.7. Middle East and Africa (MEA) 13.4. Market Attractiveness Analysis By Region 14. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. USA 14.3.1.2. Canada 14.3.2. By Form 14.3.3. By Prescription Type 14.3.4. By Route of Administration 14.3.5. By Treatment 14.3.6. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Form 14.4.3. By Prescription Type 14.4.4. By Route of Administration 14.4.5. By Treatment 14.4.6. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. USA Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Form 14.8.1.2.2. By Prescription Type 14.8.1.2.3. By Route of Administration 14.8.1.2.4. By Treatment 14.8.1.2.5. By Distribution Channel 14.8.2. Canada Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Form 14.8.2.2.2. By Prescription Type 14.8.2.2.3. By Route of Administration 14.8.2.2.4. By Treatment 14.8.2.2.5. By Distribution Channel 15. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Mexico 15.3.1.2. Brazil 15.3.1.3. Argentina 15.3.1.4. Rest of Latin America 15.3.2. By Form 15.3.3. By Prescription Type 15.3.4. By Route of Administration 15.3.5. By Treatment 15.3.6. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Form 15.4.3. By Prescription Type 15.4.4. By Route of Administration 15.4.5. By Treatment 15.4.6. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. Mexico Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Form 15.8.1.2.2. By Prescription Type 15.8.1.2.3. By Route of Administration 15.8.1.2.4. By Treatment 15.8.1.2.5. By Distribution Channel 15.8.2. Brazil Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Form 15.8.2.2.2. By Prescription Type 15.8.2.2.3. By Route of Administration 15.8.2.2.4. By Treatment 15.8.2.2.5. By Distribution Channel 15.8.3. Argentina Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Form 15.8.3.2.2. By Prescription Type 15.8.3.2.3. By Route of Administration 15.8.3.2.4. By Treatment 15.8.3.2.5. By Distribution Channel 16. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. United kingdom 16.3.1.2. Germany 16.3.1.3. France 16.3.1.4. Italy 16.3.1.5. Spain 16.3.1.6. BENELUX 16.3.1.7. Russia 16.3.1.8. Rest of Europe 16.3.2. By Form 16.3.3. By Prescription Type 16.3.4. By Route of Administration 16.3.5. By Treatment 16.3.6. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Form 16.4.3. By Prescription Type 16.4.4. By Route of Administration 16.4.5. By Treatment 16.4.6. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. United kingdom Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Form 16.8.1.2.2. By Prescription Type 16.8.1.2.3. By Route of Administration 16.8.1.2.4. By Treatment 16.8.1.2.5. By Distribution Channel 16.8.2. Germany Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Form 16.8.2.2.2. By Prescription Type 16.8.2.2.3. By Route of Administration 16.8.2.2.4. By Treatment 16.8.2.2.5. By Distribution Channel 16.8.3. France Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Form 16.8.3.2.2. By Prescription Type 16.8.3.2.3. By Route of Administration 16.8.3.2.4. By Treatment 16.8.3.2.5. By Distribution Channel 16.8.4. Italy Market Analysis 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast by Market Taxonomy 16.8.4.2.1. By Form 16.8.4.2.2. By Prescription Type 16.8.4.2.3. By Route of Administration 16.8.4.2.4. By Treatment 16.8.4.2.5. By Distribution Channel 16.8.5. Spain Market Analysis 16.8.5.1. Introduction 16.8.5.2. Market Analysis and Forecast by Market Taxonomy 16.8.5.2.1. By Form 16.8.5.2.2. By Prescription Type 16.8.5.2.3. By Route of Administration 16.8.5.2.4. By Treatment 16.8.5.2.5. By Distribution Channel 16.8.6. BENELUX Market Analysis 16.8.6.1. Introduction 16.8.6.2. Market Analysis and Forecast by Market Taxonomy 16.8.6.2.1. By Form 16.8.6.2.2. By Prescription Type 16.8.6.2.3. By Route of Administration 16.8.6.2.4. By Treatment 16.8.6.2.5. By Distribution Channel 16.8.7. Russia Market Analysis 16.8.7.1. Introduction 16.8.7.2. Market Analysis and Forecast by Market Taxonomy 16.8.7.2.1. By Form 16.8.7.2.2. By Prescription Type 16.8.7.2.3. By Route of Administration 16.8.7.2.4. By Treatment 16.8.7.2.5. By Distribution Channel 17. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Form 17.3.3. By Prescription Type 17.3.4. By Route of Administration 17.3.5. By Treatment 17.3.6. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Form 17.4.3. By Prescription Type 17.4.4. By Route of Administration 17.4.5. By Treatment 17.4.6. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. China Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Form 17.8.1.2.2. By Prescription Type 17.8.1.2.3. By Route of Administration 17.8.1.2.4. By Treatment 17.8.1.2.5. By Distribution Channel 17.8.2. Japan Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Form 17.8.2.2.2. By Prescription Type 17.8.2.2.3. By Route of Administration 17.8.2.2.4. By Treatment 17.8.2.2.5. By Distribution Channel 17.8.3. South Korea Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Form 17.8.3.2.2. By Prescription Type 17.8.3.2.3. By Route of Administration 17.8.3.2.4. By Treatment 17.8.3.2.5. By Distribution Channel 18. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. India 18.3.1.2. Malaysia 18.3.1.3. Thailand 18.3.1.4. Indonesia 18.3.1.5. Rest of South Asia 18.3.2. By Form 18.3.3. By Prescription Type 18.3.4. By Route of Administration 18.3.5. By Treatment 18.3.6. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Form 18.4.3. By Prescription Type 18.4.4. By Route of Administration 18.4.5. By Treatment 18.4.6. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. India Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Form 18.8.1.2.2. By Prescription Type 18.8.1.2.3. By Route of Administration 18.8.1.2.4. By Treatment 18.8.1.2.5. By Distribution Channel 18.8.2. Malaysia Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Form 18.8.2.2.2. By Prescription Type 18.8.2.2.3. By Route of Administration 18.8.2.2.4. By Treatment 18.8.2.2.5. By Distribution Channel 18.8.3. Thailand Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Form 18.8.3.2.2. By Prescription Type 18.8.3.2.3. By Route of Administration 18.8.3.2.4. By Treatment 18.8.3.2.5. By Distribution Channel 18.8.4. Indonesia Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Form 18.8.4.2.2. By Prescription Type 18.8.4.2.3. By Route of Administration 18.8.4.2.4. By Treatment 18.8.4.2.5. By Distribution Channel 19. Oceania Market 2018 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. Australia 19.3.1.2. New Zealand 19.3.2. By Form 19.3.3. By Prescription Type 19.3.4. By Route of Administration 19.3.5. By Treatment 19.3.6. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Form 19.4.3. By Prescription Type 19.4.4. By Route of Administration 19.4.5. By Treatment 19.4.6. By Distribution Channel 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis & Forecast 19.8.1. Australia Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Form 19.8.1.2.2. By Prescription Type 19.8.1.2.3. By Route of Administration 19.8.1.2.4. By Treatment 19.8.1.2.5. By Distribution Channel 19.8.2. New Zealand Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Form 19.8.2.2.2. By Prescription Type 19.8.2.2.3. By Route of Administration 19.8.2.2.4. By Treatment 19.8.2.2.5. By Distribution Channel 20. Middle East and Africa (MEA) Market Analysis 2018 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 20.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 20.3.1. By Country 20.3.1.1. GCC Countries 20.3.1.2. Türkiye 20.3.1.3. South Africa 20.3.1.4. Israel 20.3.1.5. North Africa 20.3.1.6. Rest of Middle East and Africa 20.3.2. By Form 20.3.3. By Prescription Type 20.3.4. By Route of Administration 20.3.5. By Treatment 20.3.6. By Distribution Channel 20.4. Market Attractiveness Analysis 20.4.1. By Country 20.4.2. By Form 20.4.3. By Prescription Type 20.4.4. By Route of Administration 20.4.5. By Treatment 20.4.6. By Distribution Channel 20.5. Market Trends 20.6. Key Market Participants - Intensity Mapping 20.7. Drivers and Restraints - Impact Analysis 20.8. Country Level Analysis & Forecast 20.8.1. GCC Countries Market Analysis 20.8.1.1. Introduction 20.8.1.2. Market Analysis and Forecast by Market Taxonomy 20.8.1.2.1. By Form 20.8.1.2.2. By Prescription Type 20.8.1.2.3. By Route of Administration 20.8.1.2.4. By Treatment 20.8.1.2.5. By Distribution Channel 20.8.2. Türkiye Market Analysis 20.8.2.1. Introduction 20.8.2.2. Market Analysis and Forecast by Market Taxonomy 20.8.2.2.1. By Form 20.8.2.2.2. By Prescription Type 20.8.2.2.3. By Route of Administration 20.8.2.2.4. By Treatment 20.8.2.2.5. By Distribution Channel 20.8.3. South Africa Market Analysis 20.8.3.1. Introduction 20.8.3.2. Market Analysis and Forecast by Market Taxonomy 20.8.3.2.1. By Form 20.8.3.2.2. By Prescription Type 20.8.3.2.3. By Route of Administration 20.8.3.2.4. By Treatment 20.8.3.2.5. By Distribution Channel 20.8.4. Israel Market Analysis 20.8.4.1. Introduction 20.8.4.2. Market Analysis and Forecast by Market Taxonomy 20.8.4.2.1. By Form 20.8.4.2.2. By Prescription Type 20.8.4.2.3. By Route of Administration 20.8.4.2.4. By Treatment 20.8.4.2.5. By Distribution Channel 20.8.5. North Africa Market Analysis 20.8.5.1. Introduction 20.8.5.2. Market Analysis and Forecast by Market Taxonomy 20.8.5.2.1. By Form 20.8.5.2.2. By Prescription Type 20.8.5.2.3. By Route of Administration 20.8.5.2.4. By Treatment 20.8.5.2.5. By Distribution Channel 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies 21.2. Market Share Analysis of Top Players 21.3. Market Presence Analysis 22. Competition Analysis 22.1. Competition Dashboard 22.2. Key Development Analysis 22.3. Branding and Promotional Strategies, by Manufacturers 22.4. Competition Deep Dive 22.4.1. Merck KGaA 22.4.1.1. Overview 22.4.1.2. Product Portfolio 22.4.1.3. Key Financials 22.4.1.4. SWOT Analysis 22.4.1.5. Key Developments 22.4.1.6. Sales Footprint 22.4.1.7. Strategy Overview 22.4.1.7.1. Marketing Strategies 22.4.1.7.2. Product Strategies 22.4.1.7.3. Channel Strategies 22.4.2. Johnson & Johnson 22.4.2.1. Overview 22.4.2.2. Product Portfolio 22.4.2.3. Key Financials 22.4.2.4. SWOT Analysis 22.4.2.5. Key Developments 22.4.2.6. Sales Footprint 22.4.2.7. Strategy Overview 22.4.2.7.1. Marketing Strategies 22.4.2.7.2. Product Strategies 22.4.2.7.3. Channel Strategies 22.4.3. Allergopharma 22.4.3.1. Overview 22.4.3.2. Product Portfolio 22.4.3.3. Key Financials 22.4.3.4. SWOT Analysis 22.4.3.5. Key Developments 22.4.3.6. Sales Footprint 22.4.3.7. Strategy Overview 22.4.3.7.1. Marketing Strategies 22.4.3.7.2. Product Strategies 22.4.3.7.3. Channel Strategies 22.4.4. Sanofi SA 22.4.4.1. Overview 22.4.4.2. Product Portfolio 22.4.4.3. Key Financials 22.4.4.4. SWOT Analysis 22.4.4.5. Key Developments 22.4.4.6. Sales Footprint 22.4.4.7. Strategy Overview 22.4.4.7.1. Marketing Strategies 22.4.4.7.2. Product Strategies 22.4.4.7.3. Channel Strategies 22.4.5. McNeil Consumer Healthcare, 22.4.5.1. Overview 22.4.5.2. Product Portfolio 22.4.5.3. Key Financials 22.4.5.4. SWOT Analysis 22.4.5.5. Key Developments 22.4.5.6. Sales Footprint 22.4.5.7. Strategy Overview 22.4.5.7.1. Marketing Strategies 22.4.5.7.2. Product Strategies 22.4.5.7.3. Channel Strategies 22.4.6. Genentech Inc. 22.4.6.1. Overview 22.4.6.2. Product Portfolio 22.4.6.3. Key Financials 22.4.6.4. SWOT Analysis 22.4.6.5. Key Developments 22.4.6.6. Sales Footprint 22.4.6.7. Strategy Overview 22.4.6.7.1. Marketing Strategies 22.4.6.7.2. Product Strategies 22.4.6.7.3. Channel Strategies 22.4.7. GlaxoSmithKline PLC 22.4.7.1. Overview 22.4.7.2. Product Portfolio 22.4.7.3. Key Financials 22.4.7.4. SWOT Analysis 22.4.7.5. Key Developments 22.4.7.6. Sales Footprint 22.4.7.7. Strategy Overview 22.4.7.7.1. Marketing Strategies 22.4.7.7.2. Product Strategies 22.4.7.7.3. Channel Strategies 22.4.8. Leti Pharma, 22.4.8.1. Overview 22.4.8.2. Product Portfolio 22.4.8.3. Key Financials 22.4.8.4. SWOT Analysis 22.4.8.5. Key Developments 22.4.8.6. Sales Footprint 22.4.8.7. Strategy Overview 22.4.8.7.1. Marketing Strategies 22.4.8.7.2. Product Strategies 22.4.8.7.3. Channel Strategies 22.4.9. Alerpharma S.A 22.4.9.1. Overview 22.4.9.2. Product Portfolio 22.4.9.3. Key Financials 22.4.9.4. SWOT Analysis 22.4.9.5. Key Developments 22.4.9.6. Sales Footprint 22.4.9.7. Strategy Overview 22.4.9.7.1. Marketing Strategies 22.4.9.7.2. Product Strategies 22.4.9.7.3. Channel Strategies 22.4.10. Allergan, Inc. 22.4.10.1. Overview 22.4.10.2. Product Portfolio 22.4.10.3. Key Financials 22.4.10.4. SWOT Analysis 22.4.10.5. Key Developments 22.4.10.6. Sales Footprint 22.4.10.7. Strategy Overview 22.4.10.7.1. Marketing Strategies 22.4.10.7.2. Product Strategies 22.4.10.7.3. Channel Strategies 22.4.11. Meda Pharmaceuticals, Inc 22.4.11.1. Overview 22.4.11.2. Product Portfolio 22.4.11.3. Key Financials 22.4.11.4. SWOT Analysis 22.4.11.5. Key Developments 22.4.11.6. Sales Footprint 22.4.11.7. Strategy Overview 22.4.11.7.1. Marketing Strategies 22.4.11.7.2. Product Strategies 22.4.11.7.3. Channel Strategies 22.4.12. Novartis International AG 22.4.12.1. Overview 22.4.12.2. Product Portfolio 22.4.12.3. Key Financials 22.4.12.4. SWOT Analysis 22.4.12.5. Key Developments 22.4.12.6. Sales Footprint 22.4.12.7. Strategy Overview 22.4.12.7.1. Marketing Strategies 22.4.12.7.2. Product Strategies 22.4.12.7.3. Channel Strategies 22.4.13. Bausch Health Companies Inc. 22.4.13.1. Overview 22.4.13.2. Product Portfolio 22.4.13.3. Key Financials 22.4.13.4. SWOT Analysis 22.4.13.5. Key Developments 22.4.13.6. Sales Footprint 22.4.13.7. Strategy Overview 22.4.13.7.1. Marketing Strategies 22.4.13.7.2. Product Strategies 22.4.13.7.3. Channel Strategies 22.4.14. Allergopharma 22.4.14.1. Overview 22.4.14.2. Product Portfolio 22.4.14.3. Key Financials 22.4.14.4. SWOT Analysis 22.4.14.5. Key Developments 22.4.14.6. Sales Footprint 22.4.14.7. Strategy Overview 22.4.14.7.1. Marketing Strategies 22.4.14.7.2. Product Strategies 22.4.14.7.3. Channel Strategies 22.4.15. ALK Abello 22.4.15.1. Overview 22.4.15.2. Product Portfolio 22.4.15.3. Key Financials 22.4.15.4. SWOT Analysis 22.4.15.5. Key Developments 22.4.15.6. Sales Footprint 22.4.15.7. Strategy Overview 22.4.15.7.1. Marketing Strategies 22.4.15.7.2. Product Strategies 22.4.15.7.3. Channel Strategies 22.4.16. Stallergenes Greer 22.4.16.1. Overview 22.4.16.2. Product Portfolio 22.4.16.3. Key Financials 22.4.16.4. SWOT Analysis 22.4.16.5. Key Developments 22.4.16.6. Sales Footprint 22.4.16.7. Strategy Overview 22.4.16.7.1. Marketing Strategies 22.4.16.7.2. Product Strategies 22.4.16.7.3. Channel Strategies 22.4.17. Allergy Therapeutics 22.4.17.1. Overview 22.4.17.2. Product Portfolio 22.4.17.3. Key Financials 22.4.17.4. SWOT Analysis 22.4.17.5. Key Developments 22.4.17.6. Sales Footprint 22.4.17.7. Strategy Overview 22.4.17.7.1. Marketing Strategies 22.4.17.7.2. Product Strategies 22.4.17.7.3. Channel Strategies 22.4.18. Aimmune Therapeutics 22.4.18.1. Overview 22.4.18.2. Product Portfolio 22.4.18.3. Key Financials 22.4.18.4. SWOT Analysis 22.4.18.5. Key Developments 22.4.18.6. Sales Footprint 22.4.18.7. Strategy Overview 22.4.18.7.1. Marketing Strategies 22.4.18.7.2. Product Strategies 22.4.18.7.3. Channel Strategies 22.4.19. Biomay AG 22.4.19.1. Overview 22.4.19.2. Product Portfolio 22.4.19.3. Key Financials 22.4.19.4. SWOT Analysis 22.4.19.5. Key Developments 22.4.19.6. Sales Footprint 22.4.19.7. Strategy Overview 22.4.19.7.1. Marketing Strategies 22.4.19.7.2. Product Strategies 22.4.19.7.3. Channel Strategies 22.4.20. HAL Allergy Group 22.4.20.1. Overview 22.4.20.2. Product Portfolio 22.4.20.3. Key Financials 22.4.20.4. SWOT Analysis 22.4.20.5. Key Developments 22.4.20.6. Sales Footprint 22.4.20.7. Strategy Overview 22.4.20.7.1. Marketing Strategies 22.4.20.7.2. Product Strategies 22.4.20.7.3. Channel Strategies 22.4.21. Bayer 22.4.21.1. Overview 22.4.21.2. Product Portfolio 22.4.21.3. Key Financials 22.4.21.4. SWOT Analysis 22.4.21.5. Key Developments 22.4.21.6. Sales Footprint 22.4.21.7. Strategy Overview 22.4.21.7.1. Marketing Strategies 22.4.21.7.2. Product Strategies 22.4.21.7.3. Channel Strategies 22.4.22. AstraZeneca 22.4.22.1. Overview 22.4.22.2. Product Portfolio 22.4.22.3. Key Financials 22.4.22.4. SWOT Analysis 22.4.22.5. Key Developments 22.4.22.6. Sales Footprint 22.4.22.7. Strategy Overview 22.4.22.7.1. Marketing Strategies 22.4.22.7.2. Product Strategies 22.4.22.7.3. Channel Strategies 23. Assumptions and Acronyms Used 24. Research Methodolog
Explore Healthcare Insights
View Reports
Seasonal Allergy Market
